DTP3

DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].

Product Specifications

CAS Number

[1809784-29-9]

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis; JAK

Type

Peptides

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dtp3.html

Purity

98.45

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O=C(N[C@H](CC1=CC=CC=C1)C(N)=O)[C@H](NC([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)CCCNC(N)=N

Molecular Formula

C26H35N7O5

Molecular Weight

525.60

Precautions

H302, H315, H319, H335

References & Citations

[1]Tornatore L, et al. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379.|[2]Tornatore L, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell. 2014 Oct 13;26 (4) :495-508.